Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Fagron NV is a pharmaceutical company specializing in pharmaceutical compounding, providing personalized medical solutions to hospitals, pharmacies, clinics, and patients across more than 30 countries. The company operates through three segments: Essentials, offering pharmaceutical raw materials and equipment; Brands, developing innovative compounding concepts and formulations; and Compounding Services, delivering ready-to-use medications from its sterile and non-sterile facilities. Founded in 1990 in Rotterdam, the Netherlands, Fagron has expanded its operations globally, with its registered office in Nazareth, Belgium, and operational headquarters in Rotterdam. The company's strategic focus on innovation and quality has enabled it to establish a significant presence in the pharmaceutical compounding market.
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
View stock

Stock highlights

Stock comparison highlights
Stock name
Fagron NVAbbVie
Last price
€23.43$294.89
Currency
EUR
USD
€1.7B$521B
18.7450.77
€1.25$5.81
0.38-
€0.28$6.83
1.20%2.35%
Sector
HealthHealth
Employees
4,88057,000
Ticker
€FAGR$ABBV
Primary listing
BSENYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in €FAGR or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.